Fuller & Thaler Asset Management
MYGN icon

Fuller & Thaler Asset Management’s Myriad Genetics MYGN Stock Holding History

Fuller & Thaler Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,800
Closed -$226K – 704
2014
Q2 		$226K Hold
5,800
– – 0.01% 416
2014
Q1 		$198K Buy
+5,800
New +$180K 0.01% 439

Other funds holding MYGN

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fuller & Thaler Asset Management's MYGN Position: Q3 2014 in Review

Fuller & Thaler Asset Management sold out of Myriad Genetics (MYGN) in Q3 2014, closing a stake of 5,800 shares — an estimated $226K sold.

Fuller & Thaler Asset Management first reported a position in MYGN in Q1 2014 and held it in 2 quarters. The position peaked at $226K in Q2 2014. 275 funds tracked by Wall St. Rank hold MYGN as of Q3 2014.

  • Fuller & Thaler Asset Management reported no remaining Myriad Genetics position as of Q3 2014 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 5,800 Myriad Genetics shares in Q3 2014, an estimated $226K.
  • Fuller & Thaler Asset Management first reported a position in Myriad Genetics in Q1 2014 and held it in 2 quarters.
  • Fuller & Thaler Asset Management's Myriad Genetics position peaked at $226K in Q2 2014.
  • 275 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2014.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.